Skip to main navigation Skip to search Skip to main content

Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer

Research output: Contribution to journalReview articlepeer-review

4 Citations (Web of Science)
Original languageEnglish
Pages (from-to)664-676
JournalBreast care (Basel, Switzerland)
Volume16
Issue number6
DOIs
Publication statusPublished - 2021

Keywords

  • PROGESTERONE-RECEPTOR
  • ESTROGEN-RECEPTOR
  • FINAL ANALYSIS
  • JOINT ANALYSIS
  • DOUBLE-BLIND
  • FOLLOW-UP
  • TRASTUZUMAB
  • CHEMOTHERAPY
  • NEUTROPENIA
  • EFFICACY

Cite this